Hims & Hers stock is a primary buy due to potential tailwinds from FDA approval of peptides and strong upcoming earnings, with the company being the largest position in the creator's portfolio.
Source Post
Hims & Hers Stock Pops 13% on Peptide News
Jul 23, 2026
Hims & Hers stock saw a significant jump following news that the FDA is considering allowing certain peptides, including BPC 157 and KPV, to be compounded and prescribed. This development could be a substantial tailwind for the company, which is also anticipating a strong earnings report on August 10th. The creator highlights that Hims & Hers is a major position in their portfolio and discusses the company's evolving ecosystem, moving towards integrated data and health insights.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
HIMSbuy opened Jul 23, 2026
-14.20%